← Back to Search

Vitamin

High Dose Vitamin A for Stem Cell Transplant Recipients

N/A
Recruiting
Led By Hannah Choe, MD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Adult patients planned to undergo an allogeneic stem cell transplant (SCT) with an human leukocyte antigen (HLA)-matched (unrelated or related) or 1 allele mismatched (7/8) donor or haploidentical donor who received either myeloablative or nonmyeloablative conditioning for hematologic malignancies are eligible
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to day 180 after stem cell transplant
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if high doses of vitamin A can help prevent gastrointestinal GVHD in people undergoing stem cell transplants.

Who is the study for?
This trial is for adults set to have a stem cell transplant from a donor who matches their human leukocyte antigen (HLA) or is slightly mismatched. They should be undergoing this procedure due to blood cancers and can have either intense or less intense pre-transplant treatments.
What is being tested?
The study tests if high doses of vitamin A can prevent gastrointestinal problems after receiving a stem cell transplant from a donor. It's in the early stages, focusing on safety and how well it works to stop these complications.
What are the potential side effects?
Potential side effects are not detailed here, but generally, high doses of vitamin A may cause headaches, dizziness, nausea, skin irritation, pain at the site of injection if given intravenously, and could potentially lead to liver damage with prolonged use.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to day 180 after stem cell transplant
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to day 180 after stem cell transplant for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Vitamin A
Secondary study objectives
Incidence of gastrointestinal graft versus host disease

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Prevention (vitamin A compound)Experimental Treatment1 Intervention
Participants receive vitamin A compound PO or enterally once prior to stem cell transplant. once over a given 24 hour period with or without food. We will re-dose at 2000 IU/kg (maximum 120,000 IU) if Week 2 Vitamin A levels remain within 10% of baseline Vitamin A.

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
340 Previous Clinical Trials
294,461 Total Patients Enrolled
Hannah Choe, MDPrincipal Investigator - Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
2 Previous Clinical Trials
272 Total Patients Enrolled

Media Library

Vitamin A Compound (Vitamin) Clinical Trial Eligibility Overview. Trial Name: NCT03719092 — N/A
Hematopoietic Stem Cell Transplant Recipient Research Study Groups: Prevention (vitamin A compound)
Hematopoietic Stem Cell Transplant Recipient Clinical Trial 2023: Vitamin A Compound Highlights & Side Effects. Trial Name: NCT03719092 — N/A
Vitamin A Compound (Vitamin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03719092 — N/A
~6 spots leftby Nov 2025